<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23949558</article-id><article-id pub-id-type="pmc">3781546</article-id><article-id pub-id-type="publisher-id">1865</article-id><article-id pub-id-type="doi">10.2337/dc12-1865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Epidemiology/Health Services Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Stratified Patient-Centered Care in Type 2 Diabetes</article-title><subtitle>A cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Slingerland</surname><given-names>Annabelle S.</given-names></name><degrees>MD</degrees><degrees>DSC</degrees><degrees>MPH</degrees><degrees>MSCHSR</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Herman</surname><given-names>William H.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Redekop</surname><given-names>William K.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dijkstra</surname><given-names>Rob F.</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jukema</surname><given-names>J. Wouter</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Niessen</surname><given-names>Louis W.</given-names></name><degrees>MD</degrees><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands</aff><aff id="aff2"><sup>2</sup>Institute of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus MC, Erasmus University Rotterdam, Rotterdam, the Netherlands</aff><aff id="aff3"><sup>3</sup>University of Michigan Medical Center, Ann Arbor, Michigan</aff><aff id="aff4"><sup>4</sup>Dutch College of General Practitioners, Utrecht, the Netherlands</aff><aff id="aff5"><sup>5</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Annabelle S. Slingerland, <email>annabelle.s.slingerland@gmail.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2013</year></pub-date><volume>36</volume><issue>10</issue><fpage>3054</fpage><lpage>3061</lpage><history><date date-type="received"><day>12</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 by the American Diabetes Association.</copyright-statement><copyright-year>2013</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="3054.pdf"></self-uri><abstract><sec><title><offsets xml_i="4639" xml_f="4648" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="4659" xml_f="4721" txt_i="21" txt_f="83">Diabetes treatment should be effective and cost-effective. HbA</offsets><sub><offsets xml_i="4726" xml_f="4728" txt_i="83" txt_f="85">1c</offsets></sub><offsets xml_i="4734" xml_f="4876" txt_i="85" txt_f="227">-associated complications are costly. Would patient-centered care be more (cost-) effective if it was targeted to patients within specific HbA</offsets><sub><offsets xml_i="4881" xml_f="4883" txt_i="227" txt_f="229">1c</offsets></sub><offsets xml_i="4889" xml_f="4897" txt_i="229" txt_f="237"> ranges?</offsets></p></sec><sec><title><offsets xml_i="4919" xml_f="4946" txt_i="239" txt_f="266">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="4957" xml_f="5134" txt_i="267" txt_f="444">This prospective, cluster-randomized, controlled trial involved 13 hospitals (clusters) in the Netherlands and 506 patients with type 2 diabetes randomized to patient-centered (</offsets><italic><offsets xml_i="5142" xml_f="5143" txt_i="444" txt_f="445">n</offsets></italic><offsets xml_i="5152" xml_f="5186" txt_i="445" txt_f="479"> = 237) or usual care (controls) (</offsets><italic><offsets xml_i="5194" xml_f="5195" txt_i="479" txt_f="480">n</offsets></italic><offsets xml_i="5204" xml_f="5248" txt_i="480" txt_f="524"> = 269). Primary outcomes were change in HbA</offsets><sub><offsets xml_i="5253" xml_f="5255" txt_i="524" txt_f="526">1c</offsets></sub><offsets xml_i="5261" xml_f="5504" txt_i="526" txt_f="769"> and quality-adjusted life years (QALYs); costs and incremental costs (USD) after 1 year were secondary outcomes. We applied nonparametric bootstrapping and probabilistic modeling over a lifetime using a validated Dutch model. The baseline HbA</offsets><sub><offsets xml_i="5509" xml_f="5511" txt_i="769" txt_f="771">1c</offsets></sub><offsets xml_i="5517" xml_f="5591" txt_i="771" txt_f="839"> strata were &lt;7.0% (53 mmol/mol), 7.0–8.5%, and &gt;8.5% (69 mmol/mol).</offsets></p></sec><sec><title><offsets xml_i="5613" xml_f="5620" txt_i="841" txt_f="848">RESULTS</offsets></title><p><offsets xml_i="5631" xml_f="5717" txt_i="849" txt_f="935">Patient-centered care was most effective and cost-effective in those with baseline HbA</offsets><sub><offsets xml_i="5722" xml_f="5724" txt_i="935" txt_f="937">1c</offsets></sub><offsets xml_i="5730" xml_f="5776" txt_i="937" txt_f="980"> &gt;8.5% (69 mmol/mol). After 1 year, the HbA</offsets><sub><offsets xml_i="5781" xml_f="5783" txt_i="980" txt_f="982">1c</offsets></sub><offsets xml_i="5789" xml_f="6081" txt_i="982" txt_f="1274"> reduction was 0.83% (95% CI 0.81–0.84%) (6.7 mmol/mol [6.5–6.8]), and the incremental cost-effectiveness ratio (ICER) was 261 USD (235–288) per QALY. Over a lifetime, 0.54 QALYs (0.30–0.78) were gained at a cost of 3,482 USD (2,706–4,258); ICER 6,443 USD/QALY (3,199–9,686). For baseline HbA</offsets><sub><offsets xml_i="6086" xml_f="6088" txt_i="1274" txt_f="1276">1c</offsets></sub><offsets xml_i="6094" xml_f="6283" txt_i="1276" txt_f="1465"> 7.0–8.5% (53–69 mmol/mol), 0.24 QALY (0.07–0.41) was gained at a cost of 4,731 USD (4,259–5,205); ICER 20,086 USD (5,979–34,193). Care was not cost-effective for patients at a baseline HbA</offsets><sub><offsets xml_i="6288" xml_f="6290" txt_i="1465" txt_f="1467">1c</offsets></sub><offsets xml_i="6296" xml_f="6320" txt_i="1467" txt_f="1488"> &lt;7.0% (53 mmol/mol).</offsets></p></sec><sec><title><offsets xml_i="6342" xml_f="6353" txt_i="1490" txt_f="1501">CONCLUSIONS</offsets></title><p><offsets xml_i="6364" xml_f="6437" txt_i="1502" txt_f="1575">Patient-centered care is more valuable when targeted to patients with HbA</offsets><sub><offsets xml_i="6442" xml_f="6444" txt_i="1575" txt_f="1577">1c</offsets></sub><offsets xml_i="6450" xml_f="6563" txt_i="1577" txt_f="1687"> &gt;8.5% (69 mmol/mol), confirming clinical intuition. The findings support treatment in those with baseline HbA</offsets><sub><offsets xml_i="6568" xml_f="6570" txt_i="1687" txt_f="1689">1c</offsets></sub><offsets xml_i="6576" xml_f="6658" txt_i="1689" txt_f="1771"> 7–8.5% (53–69 mmol/mol) and demonstrate little to no benefit among those with HbA</offsets><sub><offsets xml_i="6663" xml_f="6665" txt_i="1771" txt_f="1773">1c</offsets></sub><offsets xml_i="6671" xml_f="6737" txt_i="1773" txt_f="1836"> &lt;7% (53 mmol/mol). Further studies should assess different HbA</offsets><sub><offsets xml_i="6742" xml_f="6744" txt_i="1836" txt_f="1838">1c</offsets></sub><offsets xml_i="6750" xml_f="6831" txt_i="1838" txt_f="1919"> strata and additional risk profiles to account for heterogeneity among patients.</offsets></p></sec></abstract><counts><page-count count="8"></page-count></counts></article-meta></front><body><p><offsets xml_i="6936" xml_f="7069" txt_i="1928" txt_f="2061">Type 2 diabetes causes an enormous economic burden in almost every country. Diabetes treatment must be both effective and efficient (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7100" xml_f="7101" txt_i="2061" txt_f="2062">1</offsets></xref><offsets xml_i="7108" xml_f="7109" txt_i="2062" txt_f="2063">–</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="7140" xml_f="7141" txt_i="2063" txt_f="2064">7</offsets></xref><offsets xml_i="7148" xml_f="7297" txt_i="2064" txt_f="2213">). In 2011, diabetes affected at least 366 million people or 5% of the world’s population (8% of adults) and was responsible for 4.6 million deaths (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7328" xml_f="7329" txt_i="2213" txt_f="2214">8</offsets></xref><offsets xml_i="7336" xml_f="7414" txt_i="2214" txt_f="2292">). The prevalence of diabetes is expected to increase to 552 million in 2030 (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7445" xml_f="7446" txt_i="2292" txt_f="2293">8</offsets></xref><offsets xml_i="7453" xml_f="7591" txt_i="2293" txt_f="2431">). In 2011, diabetes care consumed at least 465 billion USD, accounting for 11% of health care expenditures in adults 20–79 years of age (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7622" xml_f="7623" txt_i="2431" txt_f="2432">8</offsets></xref><offsets xml_i="7630" xml_f="7778" txt_i="2432" txt_f="2580">). The main cause of the high-cost burden of diabetes is its acute and chronic complications, leading to a 3–13-fold increase in costs per patient (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="7809" xml_f="7810" txt_i="2580" txt_f="2581">9</offsets></xref><offsets xml_i="7817" xml_f="7818" txt_i="2581" txt_f="2582">–</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="7850" xml_f="7852" txt_i="2582" txt_f="2584">14</offsets></xref><offsets xml_i="7859" xml_f="8168" txt_i="2584" txt_f="2893">). The occurrence of complications is related to nonmodifiable risk factors such as age, sex, and socioeconomic status. It is also related to modifiable risk factors, such as BMI and waist circumference, as well as risk factors not directly related to diabetes, such as comorbidities including depression. HbA</offsets><sub><offsets xml_i="8173" xml_f="8175" txt_i="2893" txt_f="2895">1c</offsets></sub><offsets xml_i="8181" xml_f="8281" txt_i="2895" txt_f="2995"> is widely monitored as a measure of the risk of complications and as a target for intervention. HbA</offsets><sub><offsets xml_i="8286" xml_f="8288" txt_i="2995" txt_f="2997">1c</offsets></sub><offsets xml_i="8294" xml_f="8393" txt_i="2997" txt_f="3096"> may also be important in defining a more comprehensive risk-based approach to diabetes management.</offsets></p><p><offsets xml_i="8400" xml_f="8495" txt_i="3097" txt_f="3192">We have previously explored patient-centered care as a treatment strategy for type 2 diabetes (</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="8527" xml_f="8529" txt_i="3192" txt_f="3194">15</offsets></xref><offsets xml_i="8536" xml_f="8537" txt_i="3194" txt_f="3195">–</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="8569" xml_f="8571" txt_i="3195" txt_f="3197">17</offsets></xref><offsets xml_i="8578" xml_f="9100" txt_i="3197" txt_f="3719">). Earlier, we conducted a cluster-randomized, controlled clinical trial that compared patient-centered care versus professional-directed and usual care (control) in 13 hospitals (clusters). Patient-centered care had very acceptable incremental cost-effectiveness ratios (ICERs) as compared with professional-directed and usual care. These findings stimulated additional studies of self-management promotion, which is presently regarded as an essential and potentially very cost-effective approach to diabetes management (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="9132" xml_f="9134" txt_i="3719" txt_f="3721">18</offsets></xref><offsets xml_i="9141" xml_f="9142" txt_i="3721" txt_f="3722">–</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="9174" xml_f="9176" txt_i="3722" txt_f="3724">20</offsets></xref><offsets xml_i="9183" xml_f="9185" txt_i="3724" txt_f="3726">).</offsets></p><p><offsets xml_i="9192" xml_f="9346" txt_i="3727" txt_f="3881">Unfortunately, most, if not all, studies focus on the average patient, whereas individual characteristics relate to the risk of developing complications (</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="9378" xml_f="9380" txt_i="3881" txt_f="3883">21</offsets></xref><offsets xml_i="9387" xml_f="9388" txt_i="3883" txt_f="3884">–</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="9420" xml_f="9422" txt_i="3884" txt_f="3886">23</offsets></xref><offsets xml_i="9429" xml_f="9464" txt_i="3886" txt_f="3921">), the effectiveness of treatment (</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="9496" xml_f="9498" txt_i="3921" txt_f="3923">23</offsets></xref><offsets xml_i="9505" xml_f="9531" txt_i="3923" txt_f="3949">), and health care costs (</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="9563" xml_f="9565" txt_i="3949" txt_f="3951">24</offsets></xref><offsets xml_i="9572" xml_f="9573" txt_i="3951" txt_f="3952">–</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="9605" xml_f="9607" txt_i="3952" txt_f="3954">26</offsets></xref><offsets xml_i="9614" xml_f="9809" txt_i="3954" txt_f="4149">). More effective and efficient diabetes care might be achieved by focusing patient-centered strategies on patients with specific risk profiles. Such approaches have infrequently been described (</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="9841" xml_f="9843" txt_i="4149" txt_f="4151">27</offsets></xref><offsets xml_i="9850" xml_f="9851" txt_i="4151" txt_f="4152">,</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="9883" xml_f="9885" txt_i="4152" txt_f="4154">28</offsets></xref><offsets xml_i="9892" xml_f="9894" txt_i="4154" txt_f="4156">).</offsets></p><p><offsets xml_i="9901" xml_f="10057" txt_i="4157" txt_f="4313">Therefore, we analyzed data from our trial using individual patient data to compare patient-centered with usual care. We stratified patients by baseline HbA</offsets><sub><offsets xml_i="10062" xml_f="10064" txt_i="4313" txt_f="4315">1c</offsets></sub><offsets xml_i="10070" xml_f="10087" txt_i="4315" txt_f="4332"> and measured HbA</offsets><sub><offsets xml_i="10092" xml_f="10094" txt_i="4332" txt_f="4334">1c</offsets></sub><offsets xml_i="10100" xml_f="10309" txt_i="4334" txt_f="4543"> and costs at 1 year, and quality-adjusted life years (QALYs) and health care costs over a lifetime. We tested the hypothesis that a policy of patient-centered care, provided to patients in higher baseline HbA</offsets><sub><offsets xml_i="10314" xml_f="10316" txt_i="4543" txt_f="4545">1c</offsets></sub><offsets xml_i="10322" xml_f="10408" txt_i="4545" txt_f="4631"> strata, would result in significantly better outcomes and more efficient health care.</offsets></p><sec id="s1"><title><offsets xml_i="10432" xml_f="10459" txt_i="4632" txt_f="4659">RESEARCH DESIGN AND METHODS</offsets></title><sec id="s2"><title><offsets xml_i="10487" xml_f="10548" txt_i="4660" txt_f="4721">Population and intervention (see CONSORT flow diagram online)</offsets></title><p><offsets xml_i="10559" xml_f="11208" txt_i="4722" txt_f="5371">We conducted a prospective cluster-randomized trial, aiming at 18 hospitals. Four did not participate and one dropped out for financial reasons. Eligible hospitals were situated across the Netherlands and met predefined eligibility criteria in terms of numbers of beds and diabetes specialist nurses. The 13 hospitals were representative of the 120 general hospitals in the Netherlands and delivered ambulatory secondary care. There was no systematic contamination due to geographical differences. The characteristics of the 13 hospitals that participated and the 5 that did not did not differ substantially. There was a small difference in mean HbA</offsets><sub><offsets xml_i="11213" xml_f="11215" txt_i="5371" txt_f="5373">1c</offsets></sub><offsets xml_i="11221" xml_f="11321" txt_i="5373" txt_f="5473"> (SD) between participating and nonparticipating hospitals (7.8 [1.2] vs. 8.0 [1.4], respectively) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="11353" xml_f="11360" txt_i="5473" txt_f="5480">Table 1</offsets></xref><offsets xml_i="11367" xml_f="13205" txt_i="5480" txt_f="7318">). In the 13 participating hospitals, internists recruited the first 150 patients with type 1 and type 2 diabetes who attended a diabetes clinic, excluding patients who were pregnant or had a poor life expectancy due to other diseases. Enrollment took place between November 1999 and March 2000. Exclusion criteria included participation in another study or being an academic hospital as we sought to study real-life day-to-day clinical care using a low-impact observational approach. After several pilot studies and preintervention baseline patient measurements, each hospital was randomized (without restrictions) to one of three intervention arms, allocating patients with type 2 diabetes into patient-centered, professional-directed, and usual care arms (see CONSORT flow diagram in Supplementary Data online). Allocation was performed by a noninvolved person, a so-called third party, outside the research group, and allocation results were concealed from the investigators until the start of the intervention. The allocation ratio was 4:4:5. Internists and patients allocated to the intervention group were aware of the allocated arm. The unit of randomization equaled the unit of analysis and was depicted as a continuous (the percentage of people benefitting) rather than as a dichotomous (success or failure) outcome. For practical reasons, and as the outcome was nonsubjective, the study was not blinded. The study design was clustered since the intervention strategy could only be implemented by a provider team with a group of patients in a single hospital outpatient setting. Without clustering by hospital, serious contamination at the hospital, patient, and provider level would have taken place. Ex ante, we made no modifications to the trial design or protocol in response to changing circumstances or allocation results.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="13253" xml_f="13260" txt_i="7319" txt_f="7326">Table 1</offsets></label><caption><p><offsets xml_i="13280" xml_f="13304" txt_i="7326" txt_f="7350">Baseline characteristics</offsets></p></caption><graphic xlink:href="3054tbl1"></graphic></table-wrap><p><offsets xml_i="13375" xml_f="13507" txt_i="7351" txt_f="7483">This article compares two trial arms (see CONSORT flow diagram online) of randomly assigned clusters, the patient-centered arm with </offsets><italic><offsets xml_i="13515" xml_f="13516" txt_i="7483" txt_f="7484">n</offsets></italic><offsets xml_i="13525" xml_f="13542" txt_i="7484" txt_f="7501"> = 240 patients (</offsets><italic><offsets xml_i="13550" xml_f="13551" txt_i="7501" txt_f="7502">n</offsets></italic><offsets xml_i="13560" xml_f="13585" txt_i="7502" txt_f="7527"> = 237 with available HbA</offsets><sub><offsets xml_i="13590" xml_f="13592" txt_i="7527" txt_f="7529">1c</offsets></sub><offsets xml_i="13598" xml_f="13659" txt_i="7529" txt_f="7590"> data at baseline) and the usual care arm with 276 patients (</offsets><italic><offsets xml_i="13667" xml_f="13668" txt_i="7590" txt_f="7591">n</offsets></italic><offsets xml_i="13677" xml_f="13702" txt_i="7591" txt_f="7616"> = 269 with available HbA</offsets><sub><offsets xml_i="13707" xml_f="13709" txt_i="7616" txt_f="7618">1c</offsets></sub><offsets xml_i="13715" xml_f="13815" txt_i="7618" txt_f="7718"> data at baseline). Both subgroups are comparable with respect to baseline patient characteristics (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13847" xml_f="13854" txt_i="7718" txt_f="7725">Table 1</offsets></xref><offsets xml_i="13861" xml_f="15063" txt_i="7725" txt_f="8927">). In the patient-centered care clusters, patients were not only seen by their internal medicine doctors and diabetes team as in usual care but additionally received detailed diabetes passports based on national guidelines that aim to educate and record results of medical examinations in order to promote shared disease management. Educational meetings for patients were organized in all of the hospitals where the diabetes passports were introduced. Physicians, diabetes specialist nurses, and dietitians attended these meetings with an opinion leader and received personal feedback with benchmarks on baseline data, adherence to key guidelines, and the use of the diabetes passports. Barriers and facilitators were discussed. Internists received personal feedback on clinical performance after 6 months as well as on the use of the diabetes passports. Leaflets and waiting room posters were also distributed. Usual care consisted of visits every 3 months to a specialized nurse and/or internist according to national evidence-based guidelines (CBO Banda Heereveen 1998, ISBN 90-6910-217-X). The standard protocol was rechecked, re-explained, re-emphasized, and followed up in the hospitals involved.</offsets></p><p><offsets xml_i="15070" xml_f="15171" txt_i="8928" txt_f="9029">Using individual patient data, we stratified all patients into three groups according to baseline HbA</offsets><sub><offsets xml_i="15176" xml_f="15178" txt_i="9029" txt_f="9031">1c</offsets></sub><offsets xml_i="15184" xml_f="15241" txt_i="9031" txt_f="9082"> (&lt;7% [53 mmol/mol], 7–8.5%, &gt;8.5% [69 mmol/mol]) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="15273" xml_f="15280" txt_i="9082" txt_f="9089">Table 1</offsets></xref><offsets xml_i="15287" xml_f="15554" txt_i="9089" txt_f="9356">) and examined the effectiveness and cost-effectiveness of patient-centered care in each stratum. The analyses described in this article were not part of the original analyses of the cluster randomized control trial and were therefore performed as secondary analyses.</offsets></p><p><offsets xml_i="15561" xml_f="16104" txt_i="9357" txt_f="9900">The institutional review board (Medical Ethics Committee of University Medical Center Nijmegen) and the Committee for Scientific Research with Human Subjects (CWOM 9810–0208) approved of the study. All patients gave written informed consent. The trial has been assigned the ISRCTN number ISRCTN3581744 at the Commissie Mensgebonden Onderzoek (CMO), with the title The Diabetes Guidelines Implementation in Hospitals Study. The full protocol can be requested from the CMO and the authors; at the time, an online trial registry was not in place.</offsets></p><p><offsets xml_i="16111" xml_f="16350" txt_i="9901" txt_f="10140">During and after the study, there were no departures from the initial study protocol. There were no changes to eligibility criteria, interventions, examinations, data collection, methods of analysis, and outcomes. The initial study had HbA</offsets><sub><offsets xml_i="16355" xml_f="16357" txt_i="10140" txt_f="10142">1c</offsets></sub><offsets xml_i="16363" xml_f="16439" txt_i="10142" txt_f="10218"> as the primary outcome measure for the sample size calculations. A mean HbA</offsets><sub><offsets xml_i="16444" xml_f="16446" txt_i="10218" txt_f="10220">1c</offsets></sub><offsets xml_i="16452" xml_f="17153" txt_i="10220" txt_f="10921"> of 7.9% (63 mmol/mol) was specified that could drop 0.5% (3.1 mmol/mol) after the intervention. α was set at 0.05 and β at 0.20. Sample sizes for cluster-randomized trials were inflated to adjust for clustering. The intracluster correlation coefficient was set at ρ = 0.01. Given a potential of four hospitals per arm and a 70% response rate, the sample size needed was 150 patients (with a single medical record) per arm. The power is further indicated by the confidence interval. Potential inconsistencies in laboratory outcomes in pre- and postmeasurements were checked by the Dutch Foundation for Quality Assessment in Clinical Laboratories, in which all hospitals participate. Calibration of HbA</offsets><sub><offsets xml_i="17158" xml_f="17160" txt_i="10921" txt_f="10923">1c</offsets></sub><offsets xml_i="17166" xml_f="17867" txt_i="10923" txt_f="11624"> was performed according to the guidelines of the National Glycohemoglobin Standardization Program. No interim analyses were warranted or performed. Using the health care perspective, our analyses of trial effect and cost include health-related outcomes and health care costs related to the individual patients for the 1-year duration of the trial and during a simulated patient lifetime. Individual patient outcome and cost data from the trial follow-up were entered into an existing national diabetes model multiple times. This model has been used and described in previous studies, including one that estimated the long-term costs of diabetes and cardiovascular complications and hospitalizations (</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="17899" xml_f="17901" txt_i="11624" txt_f="11626">15</offsets></xref><offsets xml_i="17908" xml_f="17910" txt_i="11626" txt_f="11628">).</offsets></p></sec><sec id="s3"><title><offsets xml_i="17940" xml_f="17959" txt_i="11630" txt_f="11649">Health effects (HbA</offsets><sub><offsets xml_i="17964" xml_f="17966" txt_i="11649" txt_f="11651">1c</offsets></sub><offsets xml_i="17972" xml_f="18016" txt_i="11651" txt_f="11695">), costs, and cost-effectiveness over 1 year</offsets></title><p><offsets xml_i="18027" xml_f="18122" txt_i="11696" txt_f="11791">The end points regarding the impact of stratification over 1 year were the effectiveness of HbA</offsets><sub><offsets xml_i="18127" xml_f="18129" txt_i="11791" txt_f="11793">1c</offsets></sub><offsets xml_i="18135" xml_f="18791" txt_i="11793" txt_f="12449"> reduction, costs, and ICERs. The latter were obtained from nonparametric bootstrapping and estimated mean (95% CI). Each of these simulations used 1,000 bootstrap samples drawn from the original dataset containing the individual patient records. Direct costs per patient were estimated and standardized by multiplying each resource use component by the unit cost and summing the results at baseline and after 1 year for the main cost drivers: costs of medication (unit costs: insulin, –497 USD; tablets, –223 USD), costs of glucose monitoring (236 USD for glucose testing once every 6 weeks), and costs of implementation strategies (3.7 USD per patient) (</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="18823" xml_f="18825" txt_i="12449" txt_f="12451">29</offsets></xref><offsets xml_i="18832" xml_f="18834" txt_i="12451" txt_f="12453">).</offsets></p></sec><sec id="s4"><title><offsets xml_i="18864" xml_f="18930" txt_i="12455" txt_f="12521">Health gain, medical costs, and cost-effectiveness over a lifetime</offsets></title><p><offsets xml_i="18941" xml_f="19458" txt_i="12522" txt_f="13039">The primary end points with respect to efficacy over a lifetime were effectiveness, QALYs (assessing the long-term complications and the excess cardiovascular morbidity and mortality associated with diabetes), as well as costs, based on the estimated events and prevalence of complications. These were estimated by extrapolating and bootstrapping individual patient data in a probabilistic cost-effectiveness analysis with 10,000 iterations using a per intervention arm validated probabilistic Markov diabetes model (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="19490" xml_f="19492" txt_i="13039" txt_f="13041">10</offsets></xref><offsets xml_i="19499" xml_f="19500" txt_i="13041" txt_f="13042">,</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="19532" xml_f="19534" txt_i="13042" txt_f="13044">30</offsets></xref><offsets xml_i="19541" xml_f="19542" txt_i="13044" txt_f="13045">–</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="19574" xml_f="19576" txt_i="13045" txt_f="13047">33</offsets></xref><offsets xml_i="19583" xml_f="19655" txt_i="13047" txt_f="13119">). Progression of diabetes complications was based on the formula β^(HbA</offsets><sub><offsets xml_i="19660" xml_f="19662" txt_i="13119" txt_f="13121">1c</offsets></sub><offsets xml_i="19668" xml_f="19674" txt_i="13121" txt_f="13127">/10) (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="19706" xml_f="19708" txt_i="13127" txt_f="13129">10</offsets></xref><offsets xml_i="19715" xml_f="19716" txt_i="13129" txt_f="13130">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="19748" xml_f="19750" txt_i="13130" txt_f="13132">31</offsets></xref><offsets xml_i="19757" xml_f="19758" txt_i="13132" txt_f="13133">,</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="19790" xml_f="19792" txt_i="13133" txt_f="13135">34</offsets></xref><offsets xml_i="19799" xml_f="19845" txt_i="13135" txt_f="13181">). We adjusted for the natural increase in HbA</offsets><sub><offsets xml_i="19850" xml_f="19852" txt_i="13181" txt_f="13183">1c</offsets></sub><offsets xml_i="19858" xml_f="20040" txt_i="13183" txt_f="13365"> over time, ageing of patients, and the age-related increase in complication risk, accounting for uncertainties by including distributions in values of input variables, including HbA</offsets><sub><offsets xml_i="20045" xml_f="20047" txt_i="13365" txt_f="13367">1c</offsets></sub><offsets xml_i="20053" xml_f="20098" txt_i="13367" txt_f="13412"> at the end of the trial and mortality risk (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="20130" xml_f="20132" txt_i="13412" txt_f="13414">10</offsets></xref><offsets xml_i="20139" xml_f="20140" txt_i="13414" txt_f="13415">,</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="20172" xml_f="20174" txt_i="13415" txt_f="13417">31</offsets></xref><offsets xml_i="20181" xml_f="20242" txt_i="13417" txt_f="13478">). We only discounted costs (3%) and did not discount QALYs (</offsets><xref ref-type="bibr" rid="B32"><offsets xml_i="20274" xml_f="20276" txt_i="13478" txt_f="13480">32</offsets></xref><offsets xml_i="20283" xml_f="20284" txt_i="13480" txt_f="13481">,</offsets><xref ref-type="bibr" rid="B33"><offsets xml_i="20316" xml_f="20318" txt_i="13481" txt_f="13483">33</offsets></xref><offsets xml_i="20325" xml_f="20430" txt_i="13483" txt_f="13588">). Costs and health outcomes of the probabilistic analyses are presented as point estimates with 95% CIs.</offsets></p></sec><sec id="s5"><title><offsets xml_i="20460" xml_f="20480" txt_i="13590" txt_f="13610">Statistical analysis</offsets></title><p><offsets xml_i="20491" xml_f="20532" txt_i="13611" txt_f="13652">The primary and secondary outcomes by HbA</offsets><sub><offsets xml_i="20537" xml_f="20539" txt_i="13652" txt_f="13654">1c</offsets></sub><offsets xml_i="20545" xml_f="20650" txt_i="13654" txt_f="13759"> strata were compared using ANOVA for continuous normally distributed variables (mean and SD, such as HbA</offsets><sub><offsets xml_i="20655" xml_f="20657" txt_i="13759" txt_f="13761">1c</offsets></sub><offsets xml_i="20663" xml_f="20823" txt_i="13761" txt_f="13921"> and age), the Kruskal-Wallis test for continuous nonnormally distributed variables (median or interquartile range), like duration of diabetes, as well as the χ</offsets><sup><offsets xml_i="20828" xml_f="20829" txt_i="13921" txt_f="13922">2</offsets></sup><offsets xml_i="20835" xml_f="20973" txt_i="13922" txt_f="14060"> test for categorical variables (numbers, sex, etc.). All tests were two tailed, and the limit of statistical significance was defined as </offsets><italic><offsets xml_i="20981" xml_f="20982" txt_i="14060" txt_f="14061">P</offsets></italic><offsets xml_i="20991" xml_f="21161" txt_i="14061" txt_f="14228"> &lt; 0.05. An intention-to-treat analysis was performed in this study. We used SPSS version 11.0 (SPSS Inc., Chicago, IL) and Excel version 9.0 (Microsoft, Seattle, WA).</offsets></p></sec></sec><sec sec-type="results" id="s6"><title><offsets xml_i="21216" xml_f="21223" txt_i="14231" txt_f="14238">RESULTS</offsets></title><p><offsets xml_i="21234" xml_f="21652" txt_i="14239" txt_f="14657">Participant flow, for each arm and for each stratum is provided in the CONSORT 2010 flow diagram online. The trial was completed after 1 year of follow-up as planned. There was no reason to stop or end prematurely. Baseline characteristics of the participating and nonparticipating hospitals were similar as were the baseline characteristics of subjects in the two arms, patient-centered and usual care, apart from HbA</offsets><sub><offsets xml_i="21657" xml_f="21659" txt_i="14657" txt_f="14659">1c</offsets></sub><offsets xml_i="21665" xml_f="21667" txt_i="14659" txt_f="14661"> (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="21699" xml_f="21706" txt_i="14661" txt_f="14668">Table 1</offsets></xref><offsets xml_i="21713" xml_f="21873" txt_i="14668" txt_f="14828">). Baseline characteristics of subjects in the three strata were also comparable, apart from longer duration of diabetes and more insulin use in the highest HbA</offsets><sub><offsets xml_i="21878" xml_f="21880" txt_i="14828" txt_f="14830">1c</offsets></sub><offsets xml_i="21886" xml_f="21896" txt_i="14830" txt_f="14840"> stratum (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="21928" xml_f="21935" txt_i="14840" txt_f="14847">Table 1</offsets></xref><offsets xml_i="21942" xml_f="21944" txt_i="14847" txt_f="14849">).</offsets></p><p><offsets xml_i="21951" xml_f="22031" txt_i="14850" txt_f="14930">A summary of the continuous outcomes in each trial arm according to stratum (HbA</offsets><sub><offsets xml_i="22036" xml_f="22038" txt_i="14930" txt_f="14932">1c</offsets></sub><offsets xml_i="22044" xml_f="22232" txt_i="14932" txt_f="15120"> reduction, QALYs, and costs) as well as the effect size representing their contrast (differences between patient-centered and usual care and the ICERs) and their 95% CIs are presented in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="22264" xml_f="22271" txt_i="15120" txt_f="15127">Table 2</offsets></xref><offsets xml_i="22278" xml_f="22279" txt_i="15127" txt_f="15128">.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="22327" xml_f="22334" txt_i="15129" txt_f="15136">Table 2</offsets></label><caption><p><offsets xml_i="22354" xml_f="22357" txt_i="15136" txt_f="15139">HbA</offsets><sub><offsets xml_i="22362" xml_f="22364" txt_i="15139" txt_f="15141">1c</offsets></sub><offsets xml_i="22370" xml_f="22494" txt_i="15141" txt_f="15265"> reduction and extra costs for patient-centered and usual care after the 1st year, and QALYs and extra costs over a lifetime</offsets></p></caption><graphic xlink:href="3054tbl2"></graphic></table-wrap><sec id="s7"><title><offsets xml_i="22582" xml_f="22601" txt_i="15266" txt_f="15285">Health effects (HbA</offsets><sub><offsets xml_i="22606" xml_f="22608" txt_i="15285" txt_f="15287">1c</offsets></sub><offsets xml_i="22614" xml_f="22656" txt_i="15287" txt_f="15329">), costs, and cost-effectiveness at 1 year</offsets></title><p><offsets xml_i="22667" xml_f="22697" txt_i="15330" txt_f="15360">Change and distribution of HbA</offsets><sub><offsets xml_i="22702" xml_f="22704" txt_i="15360" txt_f="15362">1c</offsets></sub><offsets xml_i="22710" xml_f="22727" txt_i="15362" txt_f="15379"> are depicted in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="22757" xml_f="22763" txt_i="15379" txt_f="15385">Fig. 1</offsets></xref><offsets xml_i="22770" xml_f="22850" txt_i="15385" txt_f="15465">. Over 1 year, the ICER for patient-centered care was highest in the highest HbA</offsets><sub><offsets xml_i="22855" xml_f="22857" txt_i="15465" txt_f="15467">1c</offsets></sub><offsets xml_i="22863" xml_f="22873" txt_i="15467" txt_f="15477"> stratum (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="22905" xml_f="22912" txt_i="15477" txt_f="15484">Table 2</offsets></xref><offsets xml_i="22919" xml_f="23081" txt_i="15484" txt_f="15646">). In general, the ICERs were quite low. Bootstrapping the results of the individual patients and plotting the gain in a cost-effectiveness plane confirmed this (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="23111" xml_f="23117" txt_i="15646" txt_f="15652">Fig. 2</offsets></xref><offsets xml_i="23124" xml_f="23166" txt_i="15652" txt_f="15694">). The scatter plots at lower baseline HbA</offsets><sub><offsets xml_i="23171" xml_f="23173" txt_i="15694" txt_f="15696">1c</offsets></sub><offsets xml_i="23179" xml_f="23231" txt_i="15696" txt_f="15748"> were in the two lower quadrants and with higher HbA</offsets><sub><offsets xml_i="23236" xml_f="23238" txt_i="15748" txt_f="15750">1c</offsets></sub><offsets xml_i="23244" xml_f="23330" txt_i="15750" txt_f="15836"> at baseline in the upper right quadrant. Hence, for the highest stratum (baseline HbA</offsets><sub><offsets xml_i="23335" xml_f="23337" txt_i="15836" txt_f="15838">1c</offsets></sub><offsets xml_i="23343" xml_f="23415" txt_i="15838" txt_f="15907"> &gt;8.5 [69 mmol/mol]), patient-centered care showed a reduction in HbA</offsets><sub><offsets xml_i="23420" xml_f="23422" txt_i="15907" txt_f="15909">1c</offsets></sub><offsets xml_i="23428" xml_f="23461" txt_i="15909" txt_f="15942"> at higher costs (dots above the </offsets><italic><offsets xml_i="23469" xml_f="23470" txt_i="15942" txt_f="15943">x</offsets></italic><offsets xml_i="23479" xml_f="23517" txt_i="15943" txt_f="15981">-axis). For patients with baseline HbA</offsets><sub><offsets xml_i="23522" xml_f="23524" txt_i="15981" txt_f="15983">1c</offsets></sub><offsets xml_i="23530" xml_f="23593" txt_i="15983" txt_f="16046"> = 7–8.5% (53–69 mmol/mol), patient-centered care showed an HbA</offsets><sub><offsets xml_i="23598" xml_f="23600" txt_i="16046" txt_f="16048">1c</offsets></sub><offsets xml_i="23606" xml_f="23686" txt_i="16048" txt_f="16128"> reduction and was cost saving in 45% of cases. For patients with a baseline HbA</offsets><sub><offsets xml_i="23691" xml_f="23693" txt_i="16128" txt_f="16130">1c</offsets></sub><offsets xml_i="23699" xml_f="23816" txt_i="16130" txt_f="16244"> &lt;7% (53 mmol/mol), the health effects were uncertain as points were divided over the left and right sides of the </offsets><italic><offsets xml_i="23824" xml_f="23825" txt_i="16244" txt_f="16245">y</offsets></italic><offsets xml_i="23834" xml_f="23882" txt_i="16245" txt_f="16293">-axis. With 64% of the points falling below the </offsets><italic><offsets xml_i="23890" xml_f="23891" txt_i="16293" txt_f="16294">x</offsets></italic><offsets xml_i="23900" xml_f="24008" txt_i="16294" txt_f="16402">-axis, there is a reasonable chance that patient-centered care would be dominant or cheaper than usual care.</offsets></p><fig id="F1" fig-type="figure" position="float"><label><offsets xml_i="24067" xml_f="24075" txt_i="16403" txt_f="16411">Figure 1</offsets></label><caption><p><italic><offsets xml_i="24103" xml_f="24104" txt_i="16411" txt_f="16412">A</offsets></italic><offsets xml_i="24113" xml_f="24128" txt_i="16412" txt_f="16427">: Change in HbA</offsets><sub><offsets xml_i="24133" xml_f="24135" txt_i="16427" txt_f="16429">1c</offsets></sub><offsets xml_i="24141" xml_f="24169" txt_i="16429" txt_f="16457"> at 1 year, according to HbA</offsets><sub><offsets xml_i="24174" xml_f="24176" txt_i="16457" txt_f="16459">1c</offsets></sub><offsets xml_i="24182" xml_f="24209" txt_i="16459" txt_f="16486"> at baseline. Change in HbA</offsets><sub><offsets xml_i="24214" xml_f="24216" txt_i="16486" txt_f="16488">1c</offsets></sub><offsets xml_i="24222" xml_f="24315" txt_i="16488" txt_f="16581"> % in the 506 patients with type 2 diabetes after 1 year of patient-centered (black crosses, </offsets><italic><offsets xml_i="24323" xml_f="24324" txt_i="16581" txt_f="16582">n</offsets></italic><offsets xml_i="24333" xml_f="24368" txt_i="16582" txt_f="16617"> = 237) or usual care (rectangles, </offsets><italic><offsets xml_i="24376" xml_f="24377" txt_i="16617" txt_f="16618">n</offsets></italic><offsets xml_i="24386" xml_f="24419" txt_i="16618" txt_f="16651"> = 269) according to baseline HbA</offsets><sub><offsets xml_i="24424" xml_f="24426" txt_i="16651" txt_f="16653">1c</offsets></sub><offsets xml_i="24432" xml_f="24492" txt_i="16653" txt_f="16713"> %. Vertical black lines represent the different strata: HbA</offsets><sub><offsets xml_i="24497" xml_f="24499" txt_i="16713" txt_f="16715">1c</offsets></sub><offsets xml_i="24505" xml_f="24561" txt_i="16715" txt_f="16765"> &lt;7 (53 mmol/mol), 7–8.5, or &gt;8.5% (69 mmol/mol). </offsets><italic><offsets xml_i="24569" xml_f="24570" txt_i="16765" txt_f="16766">B</offsets></italic><offsets xml_i="24579" xml_f="24584" txt_i="16766" txt_f="16771">: HbA</offsets><sub><offsets xml_i="24589" xml_f="24591" txt_i="16771" txt_f="16773">1c</offsets></sub><offsets xml_i="24597" xml_f="24667" txt_i="16773" txt_f="16843"> distribution of 506 type 2 diabetic patients at 1-year follow-up. HbA</offsets><sub><offsets xml_i="24672" xml_f="24674" txt_i="16843" txt_f="16845">1c</offsets></sub><offsets xml_i="24680" xml_f="24751" txt_i="16845" txt_f="16916"> distribution of the 506 patients with type 2 diabetes according to HbA</offsets><sub><offsets xml_i="24756" xml_f="24758" txt_i="16916" txt_f="16918">1c</offsets></sub><offsets xml_i="24764" xml_f="24824" txt_i="16918" txt_f="16978"> strata after having received patient-centered (black bars, </offsets><italic><offsets xml_i="24832" xml_f="24833" txt_i="16978" txt_f="16979">n</offsets></italic><offsets xml_i="24842" xml_f="24876" txt_i="16979" txt_f="17013"> = 237) or usual care (gray bars, </offsets><italic><offsets xml_i="24884" xml_f="24885" txt_i="17013" txt_f="17014">n</offsets></italic><offsets xml_i="24894" xml_f="24913" txt_i="17014" txt_f="17033"> = 269) for 1 year.</offsets></p></caption><graphic xlink:href="3054fig1"></graphic></fig><fig id="F2" fig-type="figure" position="float"><label><offsets xml_i="25029" xml_f="25037" txt_i="17034" txt_f="17042">Figure 2</offsets></label><caption><p><offsets xml_i="25057" xml_f="25231" txt_i="17042" txt_f="17216">Cost-effectiveness plane of patient-centered over usual care. Results for incremental 1-year cost-effectiveness of patient-centered vs. usual care, according to strata of HbA</offsets><sub><offsets xml_i="25236" xml_f="25238" txt_i="17216" txt_f="17218">1c</offsets></sub><offsets xml_i="25244" xml_f="25325" txt_i="17218" txt_f="17299"> % at baseline in 506 patients. Distribution of the cost-effectiveness plane: HbA</offsets><sub><offsets xml_i="25330" xml_f="25332" txt_i="17299" txt_f="17301">1c</offsets></sub><offsets xml_i="25338" xml_f="25437" txt_i="17301" txt_f="17397"> &lt;7% (53 mmol/mol) shows 29% in the lower left quadrant and 64% in the dominant lower right. HbA</offsets><sub><offsets xml_i="25442" xml_f="25444" txt_i="17397" txt_f="17399">1c</offsets></sub><offsets xml_i="25450" xml_f="25564" txt_i="17399" txt_f="17513"> = 7–8.5% (53–69 mmol/mol) shows 45% in the dominant lower right quadrant and 56% in the upper right quadrant. HbA</offsets><sub><offsets xml_i="25569" xml_f="25571" txt_i="17513" txt_f="17515">1c</offsets></sub><offsets xml_i="25577" xml_f="25658" txt_i="17515" txt_f="17593"> &gt;8.5% (69 mmol/mol) always results in health gains and shows no cost savings.</offsets></p></caption><graphic xlink:href="3054fig2"></graphic></fig></sec><sec id="s8"><title><offsets xml_i="25745" xml_f="25788" txt_i="17595" txt_f="17638">Lifetime extrapolation of costs and effects</offsets></title><p><offsets xml_i="25799" xml_f="25919" txt_i="17639" txt_f="17759">The difference in total lifetime QALYs between patient-centered care and usual care varied according to the baseline HbA</offsets><sub><offsets xml_i="25924" xml_f="25926" txt_i="17759" txt_f="17761">1c</offsets></sub><offsets xml_i="25932" xml_f="25942" txt_i="17761" txt_f="17771"> stratum (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="25974" xml_f="25981" txt_i="17771" txt_f="17778">Table 2</offsets></xref><offsets xml_i="25988" xml_f="26044" txt_i="17778" txt_f="17834">), and the difference was positively associated with HbA</offsets><sub><offsets xml_i="26049" xml_f="26051" txt_i="17834" txt_f="17836">1c</offsets></sub><offsets xml_i="26057" xml_f="26142" txt_i="17836" txt_f="17921">. The gain achievable from patient-centered care was greatest in patients with an HbA</offsets><sub><offsets xml_i="26147" xml_f="26149" txt_i="17921" txt_f="17923">1c</offsets></sub><offsets xml_i="26155" xml_f="26227" txt_i="17923" txt_f="17992"> &gt;8.5% (0.54) (69 mmol/mol) (0.36) and lowest in patients with an HbA</offsets><sub><offsets xml_i="26232" xml_f="26234" txt_i="17992" txt_f="17994">1c</offsets></sub><offsets xml_i="26240" xml_f="26323" txt_i="17994" txt_f="18074"> &lt;7% (53 mmol/mol). In both arms, costs were higher, the higher the baseline HbA</offsets><sub><offsets xml_i="26328" xml_f="26330" txt_i="18074" txt_f="18076">1c</offsets></sub><offsets xml_i="26336" xml_f="26483" txt_i="18076" txt_f="18223">, and the difference was lowest in the highest stratum. Hence, the ICER of patient-centered over usual care was most favorable in patients with HbA</offsets><sub><offsets xml_i="26488" xml_f="26490" txt_i="18223" txt_f="18225">1c</offsets></sub><offsets xml_i="26496" xml_f="26634" txt_i="18225" txt_f="18357"> &gt;8.5% (69 mmol/mol) (6,443 USD/QALY). The higher cost-effectiveness ratio of 20,086 USD/QALY measured in the second stratum (7&lt; HbA</offsets><sub><offsets xml_i="26639" xml_f="26641" txt_i="18357" txt_f="18359">1c</offsets></sub><offsets xml_i="26647" xml_f="26803" txt_i="18359" txt_f="18512"> &lt;8.5 [53–69 mmol/mol]) was below prevailing thresholds used to decide whether or not an intervention is cost-effective (e.g., 50,000 USD for the U.S.) (</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="26835" xml_f="26837" txt_i="18512" txt_f="18514">35</offsets></xref><offsets xml_i="26844" xml_f="26870" txt_i="18514" txt_f="18540">). The lowest stratum (HbA</offsets><sub><offsets xml_i="26875" xml_f="26877" txt_i="18540" txt_f="18542">1c</offsets></sub><offsets xml_i="26883" xml_f="26959" txt_i="18542" txt_f="18615"> &lt;7 [53 mmol/mol]) showed uncertain health gains and an unfavorable ICER.</offsets></p><p><offsets xml_i="26966" xml_f="27079" txt_i="18616" txt_f="18729">The cluster design did not change the outcomes of the analyses. The intracluster-correlation for reduction in HbA</offsets><sub><offsets xml_i="27084" xml_f="27086" txt_i="18729" txt_f="18731">1c</offsets></sub><offsets xml_i="27092" xml_f="27158" txt_i="18731" txt_f="18797"> and other long-term parameters was low and varied, except for HbA</offsets><sub><offsets xml_i="27163" xml_f="27165" txt_i="18797" txt_f="18799">1c</offsets></sub><offsets xml_i="27171" xml_f="27239" txt_i="18799" txt_f="18864"> &lt;7% (53 mmol/mol) for life years and QALYs. The latter was 0.06.</offsets></p><p><offsets xml_i="27246" xml_f="27370" txt_i="18865" txt_f="18989">Analyses were only performed according to predefined protocol. No adverse events, harms, or unintended events were reported.</offsets></p></sec></sec><sec sec-type="conclusions" id="s9"><title><offsets xml_i="27429" xml_f="27440" txt_i="18992" txt_f="19003">CONCLUSIONS</offsets></title><p><offsets xml_i="27451" xml_f="27627" txt_i="19004" txt_f="19180">Stratification is an important tool to optimize effectiveness and efficiency. Patient-centered care is more effective when targeted at a subgroup defined by higher baseline HbA</offsets><sub><offsets xml_i="27632" xml_f="27634" txt_i="19180" txt_f="19182">1c</offsets></sub><offsets xml_i="27640" xml_f="27756" txt_i="19182" txt_f="19298">. Over a lifetime, patient-centered care is particularly effective and a “better buy” for patients with baseline HbA</offsets><sub><offsets xml_i="27761" xml_f="27763" txt_i="19298" txt_f="19300">1c</offsets></sub><offsets xml_i="27769" xml_f="27850" txt_i="19300" txt_f="19378"> &gt;8.5% (69 mmol/mol) and does not provide value for patients with baseline HbA</offsets><sub><offsets xml_i="27855" xml_f="27857" txt_i="19378" txt_f="19380">1c</offsets></sub><offsets xml_i="27863" xml_f="27971" txt_i="19380" txt_f="19485"> &lt;7% (53 mmol/mol). This suggests that patient-centered care should focus on patients with a baseline HbA</offsets><sub><offsets xml_i="27976" xml_f="27978" txt_i="19485" txt_f="19487">1c</offsets></sub><offsets xml_i="27984" xml_f="28041" txt_i="19487" txt_f="19541"> &gt;8.5% (69 mmol/mol), be considered for those with HbA</offsets><sub><offsets xml_i="28046" xml_f="28048" txt_i="19541" txt_f="19543">1c</offsets></sub><offsets xml_i="28054" xml_f="28133" txt_i="19543" txt_f="19622"> = 7.0–8.5% (53–69 mmol/mol), and not be implemented in those with baseline HbA</offsets><sub><offsets xml_i="28138" xml_f="28140" txt_i="19622" txt_f="19624">1c</offsets></sub><offsets xml_i="28146" xml_f="28168" txt_i="19624" txt_f="19643"> &lt;7% (53 mmol/mol).</offsets></p><p><offsets xml_i="28175" xml_f="28318" txt_i="19644" txt_f="19787">This article transforms intuition into evidence and quantifies the benefits of targeting the patient-centered care intervention by baseline HbA</offsets><sub><offsets xml_i="28323" xml_f="28325" txt_i="19787" txt_f="19789">1c</offsets></sub><offsets xml_i="28331" xml_f="28474" txt_i="19789" txt_f="19932">. Exploring additional criteria for stratification, as well as additional interventions aimed at the high-risk patient groups, seems warranted.</offsets></p><p><offsets xml_i="28481" xml_f="28807" txt_i="19933" txt_f="20259">Our study is among the first to stratify patients with type 2 diabetes according to baseline risk in order to optimize lifetime benefits and lower costs. Our results are consistent with the recent literature on cost-effectiveness of interventions in people at high risk for diabetes and stratified analyses in other diseases (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="28839" xml_f="28841" txt_i="20259" txt_f="20261">18</offsets></xref><offsets xml_i="28848" xml_f="28849" txt_i="20261" txt_f="20262">,</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="28881" xml_f="28883" txt_i="20262" txt_f="20264">34</offsets></xref><offsets xml_i="28890" xml_f="28891" txt_i="20264" txt_f="20265">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="28923" xml_f="28925" txt_i="20265" txt_f="20267">36</offsets></xref><offsets xml_i="28932" xml_f="28933" txt_i="20267" txt_f="20268">–</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="28965" xml_f="28967" txt_i="20268" txt_f="20270">40</offsets></xref><offsets xml_i="28974" xml_f="29137" txt_i="20270" txt_f="20433">). A recent Cochrane review suggests a benefit of individual education on glycemic control when compared with usual care in a subgroup of those with a baseline HbA</offsets><sub><offsets xml_i="29142" xml_f="29144" txt_i="20433" txt_f="20435">1c</offsets></sub><offsets xml_i="29150" xml_f="29206" txt_i="20435" txt_f="20488"> &gt;8% (64 mmol/mol) in an at least 6-month follow-up (</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="29238" xml_f="29240" txt_i="20488" txt_f="20490">41</offsets></xref><offsets xml_i="29247" xml_f="29327" txt_i="20490" txt_f="20570">). We extend these findings over a lifetime and show that such benefits persist.</offsets></p><p><offsets xml_i="29334" xml_f="30053" txt_i="20571" txt_f="21290">Several limitations should be acknowledged. Further studies should replicate and refine these analyses and include other risk profiles to account for heterogeneity among patients. This would also provide a more comprehensive picture of the additional key risk factors impacting the development of complications. Also, further studies should include primary care settings since treatment of chronic diseases like type 2 diabetes tends to occur in primary care settings. In addition, longer follow-up will be needed. We assumed that the level of improvement seen after 1 year would be maintained over a lifetime (as shown in the UK Prospective Diabetes Study [UKPDS]). This is especially relevant for the stratum with HbA</offsets><sub><offsets xml_i="30058" xml_f="30060" txt_i="21290" txt_f="21292">1c</offsets></sub><offsets xml_i="30066" xml_f="30379" txt_i="21292" txt_f="21602"> &gt;8.5% (69 mmol/mol). Another potential limitation could relate to the generalizability of our findings. Although it is likely that our findings apply to other European and North American hospital settings, since the prevalence, characteristics, treatment strategies, and costs of type 2 diabetes are similar (</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="30411" xml_f="30413" txt_i="21602" txt_f="21604">37</offsets></xref><offsets xml_i="30420" xml_f="30684" txt_i="21604" txt_f="21868">), the intensity of care might vary. Finally, more complex models might be needed that include side effects and disutilities related to insulin and oral medication use and other health care costs (related to patient admissions, primary care, or specialist visits).</offsets></p><p><offsets xml_i="30691" xml_f="31431" txt_i="21869" txt_f="22609">Further insight can be achieved by replication of the present approach in larger completed studies hypothesizing gradients or threshold levels below which patient-centered care is not cost-effective and above which it is cost saving. Moreover, a study using a priori stratification would provide valuable confirmatory evidence for the findings of our exploratory study. Conceptually, the terminology and emphasis of patient-centered care has evolved over the years. At the time of our study, it referred to care in which the patient through the use of self-monitoring was more involved in decision making than those enrolled in usual care. The current concept of patient-centered care is one where the patient plays a much more active role.</offsets></p><p><offsets xml_i="31438" xml_f="31840" txt_i="22610" txt_f="23012">For now, our results have several implications. When faced with the question of whether intervention A is effective and cost-effective relative to intervention B, the answer may be “it depends” instead of an unequivocal “yes” or “no,” when referring to the average patient. Targeting treatments at specific risk groups may result in better outcomes and better use of resources. Targeting those with HbA</offsets><sub><offsets xml_i="31845" xml_f="31847" txt_i="23012" txt_f="23014">1c</offsets></sub><offsets xml_i="31853" xml_f="32075" txt_i="23014" txt_f="23233"> &gt;8.5% (69 mmol/mol), those who are most in need, is preferable to targeting those who have little to gain. Especially in low- and middle-income countries, targeted implementation might reduce health care expenditures (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="32106" xml_f="32107" txt_i="23233" txt_f="23234">3</offsets></xref></p><p><offsets xml_i="32121" xml_f="32225" txt_i="23235" txt_f="23339">Future research should confirm our findings in primary care and investigate risk profiles other than HbA</offsets><sub><offsets xml_i="32230" xml_f="32232" txt_i="23339" txt_f="23341">1c</offsets></sub><offsets xml_i="32238" xml_f="32353" txt_i="23341" txt_f="23456">. These might include BMI or waist circumference or cardiovascular risk factors that predict cardiovascular events.</offsets></p><p><offsets xml_i="32360" xml_f="32574" txt_i="23457" txt_f="23671">Targeting interventions to the highest risk population may allow resources to be better used, costs to be reduced, and negative side effects to be reduced by avoiding unnecessary use of medications. Focusing on HbA</offsets><sub><offsets xml_i="32579" xml_f="32581" txt_i="23671" txt_f="23673">1c</offsets></sub><offsets xml_i="32587" xml_f="32618" txt_i="23673" txt_f="23704"> and examining a variety of HbA</offsets><sub><offsets xml_i="32623" xml_f="32625" txt_i="23704" txt_f="23706">1c</offsets></sub><offsets xml_i="32631" xml_f="32722" txt_i="23706" txt_f="23797"> reduction strategies is valuable for patients, health care organizations, and the economy.</offsets></p></sec></body><back><fn-group><fn id="fn1" fn-type="supplementary-material"><p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1865/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-1865/-/DC1</ext-link>.</p></fn><fn id="fn2"><p>Clinical trial reg. no. ISRCTN35851744, <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.org">www.isrctn.org</ext-link>.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This trial was funded by a grant from the Netherlands Ministry of Health, Welfare, and Sport.</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>The sponsor had no involvement in the design, execution, and report of this study.</p><p>A.S.S. collected, researched, and discussed the data and wrote, reviewed, and edited the manuscript. W.H.H. and J.W.J. contributed to discussion and reviewed and edited the manuscript. W.K.R. researched the data, contributed to the discussion, and reviewed and edited the manuscript. R.F.D. collected and researched the data, contributed to the discussion, and reviewed and edited the manuscript. L.W.N. collected and researched the data, contributed to the discussion, and reviewed and edited the manuscript. L.W.N. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p>The authors thank all patients and their doctors and other health staff at the affiliated institutions and elsewhere, W.S.H. van Rijn-d’Hane and C. van Rijn (Leiden University Medical Center, Leiden, the Netherlands) for navigating with effectiveness and cost-effectiveness through generations, and Dr. Willem Jan Meerding and Ewout W. Steyerberg (Center for Medical Decision Making, Department of Public Health, Erasmus University Rotterdam, Rotterdam, the Netherlands) for suggestions and statistical approval. The authors thank the reviewers for their valuable suggestions.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Barker</surname><given-names>LE</given-names></name><name><surname>Chowdhury</surname><given-names>FM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group>
<article-title>Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>1872</fpage>–<lpage>1894</lpage><pub-id pub-id-type="pmid">20668156</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>CDC Diabetes Cost-effectiveness Group</collab></person-group>
<article-title>Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes</article-title>. <source>JAMA</source>
<year>2002</year>;<volume>287</volume>:<fpage>2542</fpage>–<lpage>2551</lpage><pub-id pub-id-type="pmid">12020335</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barceló</surname><given-names>A</given-names></name><name><surname>Aedo</surname><given-names>C</given-names></name><name><surname>Rajpathak</surname><given-names>S</given-names></name><name><surname>Robles</surname><given-names>S</given-names></name></person-group>
<article-title>The cost of diabetes in Latin America and the Caribbean</article-title>. <source>Bull World Health Organ</source>
<year>2003</year>;<volume>81</volume>:<fpage>19</fpage>–<lpage>27</lpage><pub-id pub-id-type="pmid">12640472</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarride</surname><given-names>JE</given-names></name><name><surname>Hopkins</surname><given-names>R</given-names></name><name><surname>Blackhouse</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment</article-title>. <source>Pharmacoeconomics</source>
<year>2010</year>;<volume>28</volume>:<fpage>255</fpage>–<lpage>277</lpage><pub-id pub-id-type="pmid">20222752</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="other">World Health Organization. <italic>Prevention of Diabetes Mellitus. Report of a WHO Study Group</italic> Geneva, World Health Org., 1994 (Tech. Rep. Ser., no. 844)</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>van Haeften</surname><given-names>TW</given-names></name></person-group>
<article-title>Type 2 diabetes: principles of pathogenesis and therapy</article-title>. <source>Lancet</source>
<year>2005</year>;<volume>365</volume>:<fpage>1333</fpage>–<lpage>1346</lpage><pub-id pub-id-type="pmid">15823385</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmet</surname><given-names>P</given-names></name><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Shaw</surname><given-names>J</given-names></name></person-group>
<article-title>Global and societal implications of the diabetes epidemic</article-title>. <source>Nature</source>
<year>2001</year>;<volume>414</volume>:<fpage>782</fpage>–<lpage>787</lpage><pub-id pub-id-type="pmid">11742409</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="webpage">International Diabetes Federation. IDF Diabetes Atlas, Fifth Edition [Internet]. Available from <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas/5e/the-global-burden">http://www.idf.org/diabetesatlas/5e/the-global-burden</ext-link>
<comment>Accessed 5 June 2013</comment></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>SD</given-names></name><name><surname>Newton</surname><given-names>K</given-names></name><name><surname>Blough</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>DK</given-names></name><name><surname>Sandhu</surname><given-names>N</given-names></name><name><surname>Wagner</surname><given-names>EH</given-names></name></person-group>
<article-title>Patient-level estimates of the cost of complications in diabetes in a managed-care population</article-title>. <source>Pharmacoeconomics</source>
<year>1999</year>;<volume>16</volume>:<fpage>285</fpage>–<lpage>295</lpage><pub-id pub-id-type="pmid">10558040</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastman</surname><given-names>RC</given-names></name><name><surname>Javitt</surname><given-names>JC</given-names></name><name><surname>Herman</surname><given-names>WH</given-names></name><etal></etal></person-group>
<article-title>Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>735</fpage>–<lpage>744</lpage><pub-id pub-id-type="pmid">9135935</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M</given-names></name><name><surname>Gaskill</surname><given-names>SP</given-names></name><name><surname>Haffner</surname><given-names>SM</given-names></name><name><surname>Stern</surname><given-names>MP</given-names></name></person-group>
<article-title>Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study</article-title>. <source>Diabetes Care</source>
<year>1998</year>;<volume>21</volume>:<fpage>1167</fpage>–<lpage>1172</lpage><pub-id pub-id-type="pmid">9653614</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab></person-group>
<article-title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)</article-title>. <source>Lancet</source>
<year>1998</year>;<volume>352</volume>:<fpage>854</fpage>–<lpage>865</lpage><pub-id pub-id-type="pmid">9742977</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab></person-group>
<article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)</article-title>. <source>Lancet</source>
<year>1998</year>;<volume>352</volume>:<fpage>837</fpage>–<lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>AA</given-names></name><name><surname>Ortegon</surname><given-names>MM</given-names></name><name><surname>Niessen</surname><given-names>LW</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><name><surname>Dekker</surname><given-names>JM</given-names></name></person-group>
<article-title>Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>2094</fpage>–<lpage>2098</lpage><pub-id pub-id-type="pmid">19875606</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleveringa</surname><given-names>FG</given-names></name><name><surname>Welsing</surname><given-names>PM</given-names></name><name><surname>van den Donk</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>258</fpage>–<lpage>263</lpage><pub-id pub-id-type="pmid">19933991</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schouten</surname><given-names>LM</given-names></name><name><surname>Niessen</surname><given-names>LW</given-names></name><name><surname>van de Pas</surname><given-names>JW</given-names></name><name><surname>Grol</surname><given-names>RP</given-names></name><name><surname>Hulscher</surname><given-names>ME</given-names></name></person-group>
<article-title>Cost-effectiveness of a quality improvement collaborative focusing on patients with diabetes</article-title>. <source>Med Care</source>
<year>2010</year>;<volume>48</volume>:<fpage>884</fpage>–<lpage>891</lpage><pub-id pub-id-type="pmid">20808258</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoerger</surname><given-names>TJ</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Hicks</surname><given-names>KA</given-names></name><name><surname>Donahue</surname><given-names>K</given-names></name><name><surname>Sorensen</surname><given-names>S</given-names></name><name><surname>Engelgau</surname><given-names>M</given-names></name></person-group>
<article-title>Screening for type 2 diabetes mellitus: a cost-effectiveness analysis</article-title>. <source>Ann Intern Med</source>
<year>2004</year>;<volume>140</volume>:<fpage>689</fpage>–<lpage>699</lpage><pub-id pub-id-type="pmid">15126252</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mensing</surname><given-names>C</given-names></name><name><surname>Boucher</surname><given-names>J</given-names></name><name><surname>Cypress</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>National standards for diabetes self-management education</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>(<issue>Suppl. 1</issue>):<fpage>S78</fpage>–<lpage>S85</lpage><pub-id pub-id-type="pmid">16373939</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillett</surname><given-names>M</given-names></name><name><surname>Dallosso</surname><given-names>HM</given-names></name><name><surname>Dixon</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost-effectiveness analysis</article-title>. <source>BMJ</source>
<year>2010</year>;<volume>341</volume>:<fpage>c4093</fpage><pub-id pub-id-type="pmid">20729270</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="other">Cobden DS, Niessen LW, Barr CE, Rutten FF, Redekop WK. Relationships among self-management, patient perceptions of care, and health economic outcomes for decision-making and clinical practice in type 2 diabetes. Value Health 2010;13:138–147</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van ‘t Riet</surname><given-names>E</given-names></name><name><surname>Rijkelijkhuizen</surname><given-names>JM</given-names></name><name><surname>Alssema</surname><given-names>M</given-names></name></person-group>, et al. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur J <source>Prev Cardiol</source>
<year>2012</year>;<volume>19</volume>:<fpage>23</fpage>–<lpage>31</lpage></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Cagliero</surname><given-names>E</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Value of risk stratification to increase the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population</article-title>. <source>J Gen Intern Med</source>
<year>2008</year>;<volume>23</volume>:<fpage>1346</fpage>–<lpage>1353</lpage><pub-id pub-id-type="pmid">18543044</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">Epidemiology of Diabetes Interventions and Complications (EDIC). <article-title>Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort</article-title>. <source>Diabetes Care</source>
<year>1999</year>;<volume>22</volume>:<fpage>99</fpage>–<lpage>111</lpage><pub-id pub-id-type="pmid">10333910</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="other">Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995;345:1616–1619</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>D</given-names></name></person-group>
<article-title>Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues</article-title>. <source>Health Econ</source>
<year>2003</year>;<volume>12</volume>:<fpage>159</fpage>–<lpage>162; discussion 163–164</lpage><pub-id pub-id-type="pmid">12563663</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willan</surname><given-names>AR</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Hoch</surname><given-names>JS</given-names></name></person-group>
<article-title>Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data</article-title>. <source>Health Econ</source>
<year>2004</year>;<volume>13</volume>:<fpage>461</fpage>–<lpage>475</lpage><pub-id pub-id-type="pmid">15127426</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>MM</given-names></name><name><surname>Tong</surname><given-names>NW</given-names></name></person-group>
<article-title>Stratifying and tailoring HbA1c control targets for adults with type 2 diabetes: interpretation of the consensus proposed by the Chinese Society of Endocrinology</article-title>. <source>J Diabetes</source>
<year>2011</year>;<volume>3</volume>:<fpage>201</fpage>–<lpage>207</lpage><pub-id pub-id-type="pmid">21631899</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>T</given-names></name><name><surname>Sandbaek</surname><given-names>A</given-names></name><name><surname>Skriver</surname><given-names>MV</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name></person-group>
<article-title>HbA1c and cardiovascular risk score identify people who may benefit from preventive interventions: a 7 year follow-up of a high-risk screening programme for diabetes in primary care (ADDITION), Denmark</article-title>. <source>Diabetologia</source>
<year>2011</year>;<volume>54</volume>:<fpage>1318</fpage>–<lpage>1326</lpage><pub-id pub-id-type="pmid">21340624</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostenbrink</surname><given-names>JB</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name></person-group>
<article-title>Standardisation of costs: the Dutch Manual for Costing in economic evaluations</article-title>. <source>Pharmacoeconomics</source>
<year>2002</year>;<volume>20</volume>:<fpage>443</fpage>–<lpage>454</lpage><pub-id pub-id-type="pmid">12093300</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redekop</surname><given-names>WK</given-names></name><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Rutten</surname><given-names>GE</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name></person-group>, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. <source>Diabetes Care</source>
<year>2002</year>;<volume>25</volume>:<fpage>458</fpage>–<lpage>463</lpage><pub-id pub-id-type="pmid">11874930</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastman</surname><given-names>RC</given-names></name><name><surname>Javitt</surname><given-names>JC</given-names></name><name><surname>Herman</surname><given-names>WH</given-names></name><etal></etal></person-group>
<article-title>Model of complications of NIDDM. I. Model construction and assumptions</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>725</fpage>–<lpage>734</lpage><pub-id pub-id-type="pmid">9135934</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravelle</surname><given-names>H</given-names></name><name><surname>Brouwer</surname><given-names>W</given-names></name><name><surname>Niessen</surname><given-names>L</given-names></name><name><surname>Postma</surname><given-names>M</given-names></name><name><surname>Rutten</surname><given-names>F.</given-names></name></person-group> Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ <year>2007</year>;16:307–317</mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>WB</given-names></name><name><surname>Niessen</surname><given-names>LW</given-names></name><name><surname>Postma</surname><given-names>MJ</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name></person-group>
<article-title>Need for differential discounting of costs and health effects in cost effectiveness analyses</article-title>. <source>BMJ</source>
<year>2005</year>;<volume>331</volume>:<fpage>446</fpage>–<lpage>448</lpage><pub-id pub-id-type="pmid">16110075</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Raikou</surname><given-names>M</given-names></name><name><surname>McGuire</surname><given-names>A</given-names></name></person-group>, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. <source>BMI</source>
<year>2000</year>;<volume>320</volume>:<fpage>1373</fpage>–<lpage>1378</lpage></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubel</surname><given-names>PA</given-names></name><name><surname>Hirth</surname><given-names>RA</given-names></name><name><surname>Chernew</surname><given-names>ME</given-names></name><name><surname>Fendrick</surname><given-names>AM</given-names></name></person-group>
<article-title>What is the price of life and why doesn’t it increase at the rate of inflation?</article-title>
<source>Arch Intern Med</source>
<year>2003</year>;<volume>163</volume>:<fpage>1637</fpage>–<lpage>1641</lpage><pub-id pub-id-type="pmid">12885677</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>DM</given-names></name><name><surname>Schlessinger</surname><given-names>L</given-names></name><name><surname>Kahn</surname><given-names>R</given-names></name></person-group> Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251–264</mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>CDC Diabetes Cost-effectiveness Group</collab></person-group>
<article-title>Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes</article-title>. <source>JAMA</source>
<year>2002</year>;<volume>287</volume>:<fpage>2542</fpage>–<lpage>2551</lpage><pub-id pub-id-type="pmid">12020335</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ES</given-names></name><name><surname>Shook</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Chin</surname><given-names>MH</given-names></name><name><surname>Meltzer</surname><given-names>DO</given-names></name></person-group>
<article-title>The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>259</fpage>–<lpage>264</lpage><pub-id pub-id-type="pmid">16443870</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="other">Clark LT. Issues in minority health: atherosclerosis and coronary heart disease in African Americans. Med Clin North Am 2005;89:977–1001,994</mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauber</surname><given-names>A</given-names></name><name><surname>Gale</surname><given-names>EA</given-names></name></person-group>
<article-title>The market in diabetes</article-title>. <source>Diabetologia</source>
<year>2006</year>;<volume>49</volume>:<fpage>247</fpage>–<lpage>252</lpage><pub-id pub-id-type="pmid">16416145</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duke</surname><given-names>SA</given-names></name><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Colagiuri</surname><given-names>R</given-names></name></person-group>
<article-title>Individual patient education for people with type 2 diabetes mellitus</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2009</year>;<volume>21</volume>:<fpage>CD005268</fpage><pub-id pub-id-type="pmid">19160249</pub-id></mixed-citation></ref></ref-list></back></article>